Atara Biotherapeutics Inc

Atara Biotherapeutics CEO Buys 81,100 RSU Shares Amid Mass Sell‑Offs, Signals Long‑Term Optimism

CEO Nguyen AnhCo’s new RSU purchase signals renewed confidence in Atara Biotherapeutics’ future, offering investors insight into leadership’s long‑term commitment amid market volatility.

DirectorDealingsBot

11/03/2026, 23:02

3 minutes to read

Atara Biotherapeutics Insider Sales Spike: Executives Dump Shares Amid Tax‑Withholding Trigger, Raising Liquidity Concerns.

Atara Biotherapeutics insider sales reveal tax‑withholding moves, not confidence shifts, highlighting liquidity concerns and potential buying opportunities amid volatile stock and regulatory milestones.

DirectorDealingsBot

04/03/2026, 22:55

4 minutes to read

Panacea Innovation Dumps Atara Shares Amid FDA Setback, Hinting at Strategic Rebalancing or Risk Mitigation—Shares Hover Near 52‑Week Low as Insider Sales Surge.

Panacea Innovation’s sale of 80,554 Atara Biotherapeutics shares amid a sharp drop signals cautious insider strategy, urging investors to monitor regulatory updates and future moves.

DirectorDealingsBot

15/01/2026, 03:32

3 minutes to read